Full-Time
Order Management Associate Scientist
GenScript
1,001-5,000 employees
Global CRO and biologics CDMO services
Compensation Overview
$60k - $75k/yr
Middlesex, NJ, USA
In Person
Master's, PhD
 Biology & Biotech (1) |
|---|
Get referred to GenScript
See people who can refer or advise you
- Master’s degree or above
- Major in Biology or related life science disciplines
- Background in the biological or biotechnology-related industry
- Strong technical competency and communication skills
- Fully understand customer project requirements
- Review order details carefully and place internal GENE orders to ensure accurate project initiation and setup
- Develop and coordinate project plans within operational scope, ensuring alignment with production capacity and timelines
- Monitor and track end-to-end project progress, ensuring milestones and delivery timelines are met
- Provide regular project status updates and communicate progress clearly through email or meetings
- Identify and analyze unexpected technical issues, provide scientific interpretation, and coordinate discussions to define resolution strategies
- Collaborate closely with production, PM, and QC teams to ensure smooth execution and high customer satisfaction
- Support continuous improvement of production workflows and platform capabilities, and complete additional assignments as required by the team lead
- Fluency in both Chinese and English is preferred
- 1+ years of relevant working experience is preferred
- Basic knowledge of molecular biology and cell biology; experience in recombinant protein/antibody expression and purification is a plus
GenScript Biotech Corporation is a global CRO and biologics CDMO. It provides services and products for life sciences, including custom gene synthesis, peptide synthesis, protein expression/purification, antibody development, and CRISPR, and it supports cell and gene therapy through its ProBio CDMO, Bestzyme enzymes, and Legend Biotech platforms. The company differentiates itself by operating across four platforms that cover research services, end-to-end therapy development, industrial enzymes, and integrated cell therapy, with a global customer base and notable collaborations such as Legend Biotech’s CAR-T program with Janssen. Its goal is to help customers accelerate drug discovery and biopharmaceutical development, scale manufacturing, and bring cell- and gene-therapy products to market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Piscataway Township, New Jersey
Founded
2002
Get referred to GenScript
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 revenue rose 27.3% to $404.2 million; adjusted profit jumped 203.3%.
- Tamarind partnership turns GenScript into AI design's wet-lab validation partner.
- TurboCHO launched in May 2026, cutting antibody timelines to five business days.
What critics are saying
- A U.S. blacklist would cripple GenScript's top-pharma relationships and force divestitures.
- U.S. lawmakers renewed China-ties scrutiny in July 2025, threatening American customer trust.
- ProBio remains loss-making, targeting positive EBITDA only by 2027, leaving execution risk.
What makes GenScript unique
- GenScript links gene synthesis, protein expression, validation, and manufacturing in one workflow.
- It serves 200,000 customers across 100-plus countries, including top-20 pharmas.
- Legend Biotech and ProBio extend discovery into CAR-T and CDMO commercialization.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Short Term Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Company Holidays
Paid Sick Days
Compassionate Leave
Jury Duty Leave
Float day
Personal days
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 3%2 year growth
↓ -1%GenScript reports 27.3% First-Half 2026 revenue growth as AI Drug Discovery business doubles. GenScript Biotech Corporation 2026-08-18 22:15 332 Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ - GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services. GenScript Biotech Corporation reports 27.3% revenue growth in the first half of 2026. The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology companies and pharmaceutical innovators. Gene-to-Protein accounted for approximately 66% of GenScript Life Science Group revenue and remained the company's primary growth engine. GenScript's Gene-to-Protein platform combines scientific expertise, automation, and global manufacturing capacity in an integrated workflow spanning discovery, experimental validation, early development, and production support. As AI increases the scale and complexity of drug discovery, these capabilities help customers validate candidates and advance programs with greater speed and reliability. "Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability," said Sherry Shao, Rotating CEO of GenScript. "We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services. By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript's role as a critical infrastructure partner for AI-enabled drug discovery." First-Half 2026 Highlights GenScript Life Science Group * Revenue of approximately US$319.0 million, up 28.8% * Adjusted gross profit of approximately US$184.5 million, up 46.1% * Adjusted operating profit of approximately US$94.0 million, up 102.8% * Gene-to-Protein accounted for approximately 66% of segment revenue and remained the primary growth engine AI-Enabled Drug Discovery * AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period * Growth reflects deeper engagement with AI drug discovery companies and increasing demand for protein engineering, biologics discovery, and development services, reinforcing GenScript's position as a validation and infrastructure partner within the AI drug discovery ecosystem * Revenue increased 34.2% on a comparable basis to approximately US$61.1 million * New orders increased 54% * Adjusted operating loss narrowed 22.5% to US$24.3 million * Continued order growth and improving operating efficiency support ProBio's expectation of achieving positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2027 * Revenue of approximately US$30.4 million, up 7.4% * Adjusted gross profit of approximately US$13.0 million, up 14.0% Integrated Capabilities Support Growth Across the Portfolio The recovery in global biopharmaceutical research activity and the expanding use of AI are increasing the number and complexity of programs moving from computational design into experimental validation, development, and production. This shift is creating demand for integrated scientific, automation, and manufacturing infrastructure that can support customers across the drug-development workflow. GenScript connects gene synthesis, protein production, antibody discovery, biologics development, automation, and global manufacturing in a single workflow. This infrastructure enables AI-focused biotechnology companies and pharmaceutical innovators to validate more candidates, identify viable programs, and advance them through early development and production without coordinating multiple service providers. To support rising demand, GenScript continues to invest across its global discovery and manufacturing network, expanding capacity, shortening turnaround times, and enhancing automation and digital workflows. These investments are improving consistency and scalability as AI-driven customer projects grow increasingly complex. Across the portfolio, ProBio benefited from growing demand for biologics development and manufacturing services while improving operating performance and building an order base that supports future revenue growth. Bestzyme continues to invest in enzyme engineering and AI-enabled synthetic biology technologies designed to improve research efficiency, reduce production costs, and accelerate new product development. GenScript enters the second half of 2026 with continued momentum across GenScript Life Science Group, ProBio, and Bestzyme, supported by a growing order base across its core businesses. The company expects higher demand, increased utilization across its global network, and further operating leverage to support continued revenue growth and profitability improvement. Ongoing investment in technology, automation, and capacity is expanding GenScript's ability to support larger and more complex AI-enabled drug discovery programs, while ProBio's growing order base and Bestzyme's enzyme engineering and AI-enabled synthetic biology capabilities provide additional platforms for long-term growth. As adoption expands across these businesses, GenScript expects to deepen customer relationships, strengthen global delivery, and build its position as a critical infrastructure partner supporting next-generation therapeutic and biotechnology innovation. Additional financial information, including consolidated and segment results, is available in GenScript's First-Half 2026 Results Announcement published on The Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the GenScript website. About GenScript Biotech Corporation Founded in New Jersey in 2002, GenScript Biotech Corporation supports biotechnology and healthcare innovation through its integrated portfolio of research, development, and manufacturing services. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has more than 6,100 employees and serves over 200,000 customers across more than 100 countries and regions, including the world's top 20 pharmaceutical companies. For more information, visit www.genscript.com. Investor and Media Contacts
GenScript reports 27.3% First-Half 2026 revenue growth as AI Drug Discovery business doubles. August 18, 2026 Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ - GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services. GenScript Biotech Corporation reports 27.3% revenue growth in the first half of 2026. The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology companies and pharmaceutical innovators. Gene-to-Protein accounted for approximately 66% of GenScript Life Science Group revenue and remained the company's primary growth engine. GenScript's Gene-to-Protein platform combines scientific expertise, automation, and global manufacturing capacity in an integrated workflow spanning discovery, experimental validation, early development, and production support. As AI increases the scale and complexity of drug discovery, these capabilities help customers validate candidates and advance programs with greater speed and reliability. "Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability," said Sherry Shao, Rotating CEO of GenScript. "We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services. By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript's role as a critical infrastructure partner for AI-enabled drug discovery." First-Half 2026 Highlights GenScript Life Science Group * Revenue of approximately US$319.0 million, up 28.8% * Adjusted gross profit of approximately US$184.5 million, up 46.1% * Adjusted operating profit of approximately US$94.0 million, up 102.8% * Gene-to-Protein accounted for approximately 66% of segment revenue and remained the primary growth engine AI-Enabled Drug Discovery * AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period * Growth reflects deeper engagement with AI drug discovery companies and increasing demand for protein engineering, biologics discovery, and development services, reinforcing GenScript's position as a validation and infrastructure partner within the AI drug discovery ecosystem * Revenue increased 34.2% on a comparable basis to approximately US$61.1 million * New orders increased 54% * Adjusted operating loss narrowed 22.5% to US$24.3 million * Continued order growth and improving operating efficiency support ProBio's expectation of achieving positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2027 * Revenue of approximately US$30.4 million, up 7.4% * Adjusted gross profit of approximately US$13.0 million, up 14.0% Integrated Capabilities Support Growth Across the Portfolio The recovery in global biopharmaceutical research activity and the expanding use of AI are increasing the number and complexity of programs moving from computational design into experimental validation, development, and production. This shift is creating demand for integrated scientific, automation, and manufacturing infrastructure that can support customers across the drug-development workflow. GenScript connects gene synthesis, protein production, antibody discovery, biologics development, automation, and global manufacturing in a single workflow. This infrastructure enables AI-focused biotechnology companies and pharmaceutical innovators to validate more candidates, identify viable programs, and advance them through early development and production without coordinating multiple service providers. To support rising demand, GenScript continues to invest across its global discovery and manufacturing network, expanding capacity, shortening turnaround times, and enhancing automation and digital workflows. These investments are improving consistency and scalability as AI-driven customer projects grow increasingly complex. Across the portfolio, ProBio benefited from growing demand for biologics development and manufacturing services while improving operating performance and building an order base that supports future revenue growth. Bestzyme continues to invest in enzyme engineering and AI-enabled synthetic biology technologies designed to improve research efficiency, reduce production costs, and accelerate new product development. GenScript enters the second half of 2026 with continued momentum across GenScript Life Science Group, ProBio, and Bestzyme, supported by a growing order base across its core businesses. The company expects higher demand, increased utilization across its global network, and further operating leverage to support continued revenue growth and profitability improvement. Ongoing investment in technology, automation, and capacity is expanding GenScript's ability to support larger and more complex AI-enabled drug discovery programs, while ProBio's growing order base and Bestzyme's enzyme engineering and AI-enabled synthetic biology capabilities provide additional platforms for long-term growth. As adoption expands across these businesses, GenScript expects to deepen customer relationships, strengthen global delivery, and build its position as a critical infrastructure partner supporting next-generation therapeutic and biotechnology innovation. Additional financial information, including consolidated and segment results, is available in GenScript's First-Half 2026 Results Announcement published on The Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the GenScript website. About GenScript Biotech Corporation Founded in New Jersey in 2002, GenScript Biotech Corporation supports biotechnology and healthcare innovation through its integrated portfolio of research, development, and manufacturing services. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has more than 6,100 employees and serves over 200,000 customers across more than 100 countries and regions, including the world's top 20 pharmaceutical companies. For more information, visit www.genscript.com. Investor and Media Contacts
GenScript Biotech reported first-half 2026 revenue of approximately $404.2 million, up 27.3% year over year, while adjusted net profit surged 203.3% to roughly $62.5 million. The company's AI-enabled drug discovery business doubled compared to the previous year, marking its third consecutive half-year of rapid growth. Gene-to-Protein accounted for about 66% of GenScript Life Science Group revenue and remained the primary growth driver. The platform combines scientific expertise, automation, and global manufacturing capacity to support drug discovery and development. GenScript Life Science Group generated revenue of approximately $319 million. ProBio revenue reached roughly $61.1 million, with the unit expecting positive adjusted EBITDA by 2027. Bestzyme reported revenue of about $30.4 million. The company attributes growth to increased demand from AI-focused biotechnology companies and pharmaceutical innovators requiring experimental validation and development services.
Genscript biotech reports higher underlying profit amid segment growth. August 16, 2026 at 10:39 AM UTC - By FilingReader AI Genscript Biotech reported group revenue of US$404,216k for the six months ended 30 June 2026, representing a 27.3% year-over-year increase on an underlying basis. Gross profit reached US$206,711k, up 48.0% underlying, while adjusted net profit climbed 203.3% to US$62,523k. However, taking into account equity accounting impacts from Legend Group, the company recorded a net loss after income tax of US$129,344k for the period. Performance across business segments showed positive momentum, led by the GenScript Life Science Group with external revenue of US$315,218k. ProBio and Bestzyme contributed external revenues of US$58,028k and US$30,387k respectively, with ProBio narrowing its adjusted operating loss and Bestzyme seeing a 7.4% revenue increase. This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact [email protected]
GenScript and Tamarind Bio partner to connect AI Molecular Design with rapid lab validation. Aug 05, 2026, 12:15 ET Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof PISCATAWAY, N.J. and SAN FRANCISCO, Aug. 5, 2026 /PRNewswire/ - Artificial intelligence can now generate thousands of potential drug molecules in the time it once took to design one, dramatically expanding what scientists can imagine. Yet deciding which designs merit further investment still depends on experimental proof. To help address that gap, GenScript Biotech Corporation and Tamarind Bio today announced a strategic partnership connecting Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab validation capabilities. Together, the companies are creating a connected validation engine for AI-enabled discovery, giving scientists a more direct path from AI-generated designs to lab-generated evidence. Through this collaboration, researchers using Tamarind Bio's platform can submit AI-generated sequences and access GenScript's end-to-end wet-lab services, including synthesis, expression, and testing. By reducing manual handoffs between design and validation, the workflow enables teams to generate biological data faster and prioritize promising candidates more efficiently. Addressing a Critical Discovery Bottleneck As AI increases the volume and diversity of molecular designs entering research pipelines, lab capacity and validation have become critical constraints. GenScript's wet-lab infrastructure helps researchers move from digital sequences to model-ready experimental data in as little as four days. With over two decades of biologics expertise, GenScript has built one of the industry's most advanced validation engines for AI-enabled discovery, helping teams evaluate more candidates and build richer datasets to support downstream discovery decisions. "AI is opening doors the industry could only imagine a few years ago," said Ray Chen, President of GenScript Life Science Group. "But biology still determines what moves forward. By connecting AI-powered design to experimental proof, this partnership is helping lay the groundwork for the next generation of scientific innovation." Expanding Access to Molecular Design Tamarind Bio's no-code platform empowers biologics and small molecule researchers with access to more than 300 computational biology models. The platform enables researchers to rapidly test and evaluate AI applications in drug discovery, then scale and execute them for full computational design campaigns. The integration with GenScript extends that capability into the lab, enabling researchers to seamlessly validate promising molecular designs through a single connected workflow. "Tamarind was built to make advanced molecular design accessible to every scientist," said Deniz Kavi, CEO and Co-Founder of Tamarind Bio. "Partnering with GenScript bridges the gap between digital design and physical experimentation, empowering scientists to turn promising candidates into actionable lab results faster than ever." Connecting Design to Decision The partnership reflects a broader shift across the discovery ecosystem: as AI expands what researchers can generate, fast and reliable experimental validation is becoming more important. By connecting AI-powered design with wet-lab validation earlier in discovery, GenScript and Tamarind Bio are enabling researchers to make faster, better-informed decisions about which programs to advance. Earlier validation of promising molecular designs could help accelerate progress across applications ranging from therapeutics and cell and gene therapy to industrial biotechnology. About GenScript Biotech Corporation Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners - from academic institutions to industry leaders - to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com. About Tamarind Bio Tamarind Bio, founded in 2023 in San Francisco, is a unified interface to 300+ molecular AI/ML tools for drug discovery. Tamarind provides scientists with a no-code web interface, AI agent or API to access leading molecular design workflows, including protein structure prediction, de novo design, and simulation. Tamarind is deployed in the majority of the top 20 pharma, and is used by tens of thousands of scientists across industry and academia. For more information, visit www.tamarind.bio.